参考文献/References:
[1]Savarese G,Stolfo D,Sinagra G,et al. Heart failure with mid-range or mildly reduced ejection fraction[J]. Nat Rev Cardiol,2022,19(2):100-116.
[2]Kaneko H,Yano Y,Itoh H,et al. Association of blood pressure classification using the 2017 American College of Cardiology/American Heart Association blood pressure guideline with risk of heart failure and atrial fibrillation[J]. Circulation, 2021, 143(23): 2244-2253.
[3]Yu H,Zhang F,Yan P,et al. LARP7 protects against heart failure by enhancing mitochondrial biogenesis[J]. Circulation,2021,143(20):2007-2022.
[4]Noma A. ATP-regulated K+ channels in cardiac muscle [J]. Nature, 1983, 305(5930): 147-148.
[5]Kao YR, Will B. The cost of competency?[J]. Cell ,2023,186(4):685-687.
[6]Guo Y,Zhang H,Yan C,et al. Small molecule agonist of mitochondrial fusion repairs mitochondrial dysfunction[J]. Nat Chem Biol,2023,19(4):468-477.
[7]Jiang X,Wu D,Jiang Z,et al. Protective effect of nicorandil on cardiac microvascular injury:role of mitochondrial integrity[J]. Oxid Med Cell Longev,2021,2021:4665632.
[8]Aziz Q,Chen J,Moyes AJ,et al. Vascular KATP channels protect from cardiac dysfunction and preserve cardiac metabolism during endotoxemia[J]. J Mol Med (Berl),2020,98(8):1149-1160.
[9]Pertiwi KR,Hillman RM,Scott CA,et al. Ischemia reperfusion injury produces, and ischemic preconditioning prevents, rat cardiac fibroblast differentiation: role of KATP channels[J]. J Cardiovasc Dev Dis,2019,6(2):22.
[10]Iguchi K,Saotome M,Yamashita K,et al. Pinacidil,a KATP channel opener,stimulates cardiac Na+/Ca2+ exchanger function through the NO/cGMP/PKG signaling pathway in guinea pig cardiac ventricular myocytes[J].Naunyn Schmiedebergs Arch Pharmacol,2019,392(8): 949-959.
[11]Bezerra Palácio P,Brito Lucas AM,Varlla de Lacerda Alexandre J,et al. Pharmacological and molecular docking studies reveal that glibenclamide competitively inhibits diazoxide-induced mitochondrial ATP-sensitive potassium channel activation and pharmacological preconditioning[J]. Eur J Pharmacol, 2021, 908: 174379.
[12]Paggio A,Checchetto V,Campo A,et al. Identification of an ATP-sensitive potassium channel in mitochondria[J]. Nature,2019,572(7771):609-613.
[13]Sakamoto K,Kurokawa J. Involvement of sex hormonal regulation of K+ channels in electrophysiological and contractile functions of muscle tissues [J]. J Pharmacol Sci, 2019,139(4):259-265.
[14]Bai XJ,Hao JT,Zheng RH,et al. Glucagon-like peptide-1 analog liraglutide attenuates pressure-overload induced cardiac hypertrophy and apoptosis through activating ATP sensitive potassium channels[J]. Cardiovasc Drugs Ther,2021,35(1):87-101.
[15]Zhang F,Zhou GH,An Q,et al. Decreased gene expression of KACh and K ATP channels in hyperthyroid rabbit atria[J]. Int J Clin Exp Pathol,2022,15(3):145-151.
[16]Singh GK,McClenaghan C,Aggarwal M,et al. A unique high-output cardiac hypertrophy phenotype arising from low systemic vascular resistance in cantu syndrome[J]. J Am Heart Assoc,2022,11(24):e027363.
[17]van Vlerken-Ysla L,Tyurina YY,Kagan VE,et al. Functional states of myeloid cells in cancer[J]. Cancer cell,2023,41(3):490-504.
[18]Cheu JW, Lee D, Li Q,et al. Ferroptosis suppressor protein 1 inhibition promotes tumor ferroptosis and anti-tumor immune responses in liver cancer[J]. Cell Mol Gastroenterol Hepatol,2023,16(1):133-159.
[19]Xu S,Li X,Li Y,et al. Neuroprotective effect of Dl-3-n-butylphthalide against ischemia-reperfusion injury is mediated by ferroptosis regulation via the SLC7A11/GSH/GPX4 pathway and the attenuation of blood-brain barrier disruption[J]. Front Aging Neurosci,2023,15:1028178.
[20]Costa I,Barbosa DJ,Benfeito S,et al. Molecular mechanisms of ferroptosis and their involvement in brain diseases[J]. Pharmacol Ther,2023,244:108373.
[21]Huang L,Feng J,Zhu J,et al. A strategy of fenton reaction cycloacceleration for high performance ferroptosis therapy initiated by tumor microenvironment remodeling[J]. Adv Healthc Mater,2023,12(18):e2203362.
[22]Chen L,Shi D,Guo M. The roles of PKC-δ and PKC-ε in myocardial ischemia/reperfusion injury[J]. Pharmacol Res,2021,170:105716.
[23]Liu X, Wang Y, Zhang H, et al. Different protein kinase C isoenzymes mediate inhibition of cardiac rapidly activating delayed rectifier K+ current by different G-protein coupled receptors[J]. Br J Pharmacol,2017,174(23):4464-4477.
[24]Rohde S,Sabri A,Kamasamudran R,et al. The alpha(1)-adrenoceptor subtype- and protein kinase C isoform-dependence of Norepinephrine’s actions in cardiomyocytes[J]. J Mol Cell Cardiol,2000,32(7):1193-1209.
[25]Huang S,Wang W,Li L,et al. P2X7 receptor deficiency ameliorates STZ-induced cardiac damage and remodeling through PKCβ and ERK[J]. Front Cell Dev Biol,2021,9:692028.
[26]Lin HJ,Mahendran R,Huang HY,et al. Aqueous extract of Solanum nigrum attenuates Angiotensin-II induced cardiac hypertrophy and improves cardiac function by repressing protein kinase C-ζ to restore HSF2 deSUMOlyation and Mel-18-IGF-IIR signaling suppression[J]. J Ethnopharmacol,2022,284:114728.
[27]Zhou R,Chen Y,Li S,et al. TRPM7 channel inhibition attenuates rheumatoid arthritis articular chondrocyte ferroptosis by suppression of the PKCα-NOX4 axis[J]. Redox Biol,2022,55:102411.
[28]Zhang HL,Hu BX,Li ZL,et al. PKCβⅡ phosphorylates ACSL4 to amplify lipid peroxidation to induce ferroptosis [J]. Nat Cell Biol,2022,24(1):88-98.
[29]Chen X,Song X,Li J,et al. Identification of HPCAL1 as a specific autophagy receptor involved in ferroptosis[J]. Autophagy,2023,19(1):54-74.
[30]Zhang X, Zheng Q, Yue X, et al. ZNF498 promotes hepatocellular carcinogenesis by suppressing p53-mediated apoptosis and ferroptosis via the attenuation of p53 Ser46 phosphorylation[J]. J Exp Clin Cancer Res,2022,41(1):79.
[31]Popov SV,Mukhomedzyanov AV,Maslov LN,et al. The infarct-reducing effect of the δ(2) opioid receptor agonist deltorphin Ⅱ:the molecular mechanism[J]. Membranes (Basel),2023,13(1):63.
[32]Ning D,Yang X,Wang T,et al. Atorvastatin treatment ameliorates cardiac function and remodeling induced by isoproterenol attack through mitigation of ferroptosis[J]. Biochem Biophys Res Commun,2021,574:39-47.
[33]Sun L,Wang H,Yu S,et al. Herceptin induces ferroptosis and mitochondrial dysfunction in H9c2?cells[J]. Int J Mol Med,2022,49(2):17.
[34]Zhang Z,Tang J,Song J,et al. Elabela alleviates ferroptosis,myocardial remodeling,fibrosis and heart dysfunction in hypertensive mice by modulating the IL-6/STAT3/GPX4 signaling[J]. Free Radic Biol Med,2022,181:130-142.
[35]Liu J,Lane S,Lall R,et al. Circulating hemopexin modulates anthracycline cardiac toxicity in patients and in mice[J]. Sci Adv,2022,8(51):eadc9245.
[36]Zhang X,Zheng C,Gao Z,et al. SLC7A11/xCT prevents cardiac hypertrophy by inhibiting ferroptosis[J]. Cardiovasc Drugs Ther,2022,36(3):437-447.
[37]Li X,Li Z,Dong X,et al. Astragaloside Ⅳ attenuates myocardial dysfunction in diabetic cardiomyopathy rats through downregulation of CD36-mediated ferroptosis [J]. Phytother Res,2023,37(7):3042-3056.
[38]Zhou J,Yu T,Wu G,et al. Pyrroloquinoline quinone modulates YAP-related anti-ferroptotic activity to protect against myocardial hypertrophy[J]. Front Pharmacol,2022,13:977385.
[39]Li S,Wen P,Zhang D,et al. PGAM5 expression levels in heart failure and protection ROS-induced oxidative stress and ferroptosis by Keap1/Nrf2[J]. Clin Exp Hypertens,2023,45(1):2162537.
[40]Zhang LL,Chen GH,Tang RJ,et al. Levosimendan reverses cardiac malfunction and cardiomyocyte ferroptosis during heart failure with preserved ejection fraction via connexin 43 signaling activation[J]. Cardiovasc Drugs Ther,2023 Mar 7. doi:10.1007/s10557-023-07441-4.
相似文献/References:
[1]袁明明 赖松青 张泽宇 吴起才.铁死亡在脓毒症心脏功能损伤中的研究进展[J].心血管病学进展,2022,(1):26.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.007]
YUAN mingmingLAI SongqingZHANG ZeyuWU Qicai.Ferroptosis in Cardiac Function Impairment in Sepsis[J].Advances in Cardiovascular Diseases,2022,(6):26.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.007]
[2]彭石 马茜钰 张丹 张兆元 张锦.铁死亡在心肌缺血再灌注损伤中的作用及靶向治疗研究进展[J].心血管病学进展,2022,(4):357.[doi:10.16806/j.cnki.issn.1004-3934.2022.04.017]
PENG Shi,MA Qianyu,ZHANG Dan,et al.Role and Targeted Treatment of Ferroptosis?n Myocardial Ischemia Reperfusion Injury[J].Advances in Cardiovascular Diseases,2022,(6):357.[doi:10.16806/j.cnki.issn.1004-3934.2022.04.017]
[3]彭可玲 贾晓艳 王华 刘永铭.铁死亡与心力衰竭的研究进展[J].心血管病学进展,2022,(5):432.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.012]
PENG Keling,JIA Xiaoyan,WANG Hua,et al.Ferroptosis and Heart Failure[J].Advances in Cardiovascular Diseases,2022,(6):432.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.012]
[4]邵亚兰 马继鹏 卢林鹤 熊祥 马燕燕 刘金成 杨剑.铁死亡与铁自噬在中的研究进展[J].心血管病学进展,2022,(9):787.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.005]
SHAO Yalan,MA Jipeng,LU Linhe,et al.Ferroptosis and Ferritinophagy in Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2022,(6):787.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.005]
[5]孙悦 付松波 李亦兰.心肌细胞铁死亡及其检测方法[J].心血管病学进展,2023,(2):167.[doi:10.16806/j.cnki.issn.1004-3934.2023.02.016]
SUN Yue,FU Songbo,LI Yilan.Methods for the Detection of Ferroptosis in Cardiomyocytes[J].Advances in Cardiovascular Diseases,2023,(6):167.[doi:10.16806/j.cnki.issn.1004-3934.2023.02.016]
[6]叶宇恒 钱玲玲 王如兴 李库林.心肌缺血再灌注损伤中铁死亡的调控机制研究进展[J].心血管病学进展,2023,(5):416.[doi:10.16806/j.cnki.issn.1004-3934.2023.05.008]
YE Yuheng,QIAN Lingling,WANG Ruxing,et al.Regulatory Mechanisms of Ferroptosis in Myocardial Ischemia Reperfusion Injury[J].Advances in Cardiovascular Diseases,2023,(6):416.[doi:10.16806/j.cnki.issn.1004-3934.2023.05.008]
[7]王文杰 杨嘉馨 丁耀东 王可馨 牛佳龙 葛海龙.铁死亡在心血管疾病中的研究进展[J].心血管病学进展,2023,(5):420.[doi:10.16806/j.cnki.issn.1004-3934.2023.05.009]
WANG Wenjie,YANG Jiaxin,DING Yaodong,et al.Ferroptosis in Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2023,(6):420.[doi:10.16806/j.cnki.issn.1004-3934.2023.05.009]
[8]于永丽 李艳 高奋.铁死亡在血管紧张素Ⅱ诱导的心肌肥大中的作用研究进展[J].心血管病学进展,2023,(12):1116.[doi:10.16806/j.cnki.issn.1004-3934.2023.12.014]
YU Yongli,LI Yan,GAO Fen.Ferroptosis in Angiotensin-Induced Cardiac hypertrophy[J].Advances in Cardiovascular Diseases,2023,(6):1116.[doi:10.16806/j.cnki.issn.1004-3934.2023.12.014]
[9]李心瑶 陈俊 李灼.脓毒症心肌病的发病机制研究进展[J].心血管病学进展,2024,(1):44.[doi:10.16806/j.cnki.issn.1004-3934.2023.01.012]
LI Xinyao,CHEN Jun,LI Zhuo.Pathogenesis of Septic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2024,(6):44.[doi:10.16806/j.cnki.issn.1004-3934.2023.01.012]
[10]赵 珂 陈晓姝 魏希进 张 娟 刘 杨 卞雨敬 袁 杰.铁死亡的调控机制及其在蒽环类药物心脏毒性中的研究进展[J].心血管病学进展,2024,(3):261.[doi:10.16806/j.cnki.issn.1004-3934.202.03.016]
First Clinical Medical College,Shandong University of Traditional Chinese Medicine,Jinan 0000,et al.Regulatory Mechanism of Ferroptosis and Its Progress in Anthracycline-Induced Cardiotoxicity[J].Advances in Cardiovascular Diseases,2024,(6):261.[doi:10.16806/j.cnki.issn.1004-3934.202.03.016]